Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 159.5% in July

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large increase in short interest in July. As of July 31st, there was short interest totaling 4,311,877 shares, an increase of 159.5% from the July 15th total of 1,661,803 shares. Currently, 15.8% of the company’s stock are short sold. Based on an average daily volume of 4,576,589 shares, the days-to-cover ratio is presently 0.9 days.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in JSPR. Engineers Gate Manager LP bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at approximately $26,000. Panagora Asset Management Inc. bought a new stake in Jasper Therapeutics during the 4th quarter worth approximately $35,000. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics during the 1st quarter worth approximately $46,000. Voleon Capital Management LP purchased a new position in Jasper Therapeutics during the third quarter valued at approximately $50,000. Finally, Jain Global LLC purchased a new stake in shares of Jasper Therapeutics in the fourth quarter worth $79,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JSPR. Wall Street Zen upgraded shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research report on Friday, May 15th. Piper Sandler started coverage on shares of Jasper Therapeutics in a report on Wednesday. They issued an “overweight” rating and a $2.00 price objective for the company. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.57.

Jasper Therapeutics Trading Up 4.8%

JSPR opened at $0.86 on Friday. Jasper Therapeutics has a 12-month low of $0.32 and a 12-month high of $3.14. The company’s 50 day moving average is $0.59 and its 200 day moving average is $0.91. The company has a market cap of $24.17 million, a price-to-earnings ratio of -0.27 and a beta of 3.02.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.08. As a group, analysts predict that Jasper Therapeutics will post -1.67 EPS for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.